Targeting secreted factors in endocrine resistant breast cancer therapy
内分泌耐药乳腺癌治疗中的靶向分泌因子
基本信息
- 批准号:10654343
- 负责人:
- 金额:$ 48万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-04-01 至 2026-03-31
- 项目状态:未结题
- 来源:
- 关键词:AntibodiesAntineoplastic AgentsAromatase InhibitorsAutomobile DrivingBindingBioinformaticsBiological AssayBiological MarkersBreast Cancer CellBreast Cancer PatientBreast Cancer cell lineBreast Cancer therapyCCR5 geneCDK4 geneCRISPR/Cas technologyCell CommunicationCell LineCell ProliferationCellsClinicalCoculture TechniquesCombined Modality TherapyCommunicationConduct Clinical TrialsDiseaseDrug TargetingDrug resistanceESR1 geneEndocrineEndoglinEstrogen ReceptorsEstrogen receptor positiveFeedbackFibroblastsFulvestrantFutureGrowthInvadedInvestigationKnock-outKnowledgeLigand Binding DomainLymphatic Endothelial CellsMAPK Signaling Pathway PathwayMacrophageMalignant NeoplasmsMammary NeoplasmsMetastatic breast cancerMethodsMigration AssayMolecular TargetMusMutationNeoplasm MetastasisOrganOutcomes ResearchPatientsPharmaceutical PreparationsPhenotypePlayPoint MutationPostmenopauseProtein SecretionRANTESRecurrenceRegimenResistanceResistance developmentRoleSecondary toSignal PathwaySignal TransductionSolid NeoplasmStromal CellsSystemTamoxifenTestingTherapeuticTissuesTubeUp-RegulationVascular Endothelial CellWomanXenograft procedurecancer clinical trialcell motilitycell stromacytokinedesigndiagnostic biomarkerdimethylbenzanthraceneeffective therapyexperimental studygenome editinghormone therapyinhibitorinhibitor therapymalignant breast neoplasmmouse modelneoplastic cellnew therapeutic targetnovelparacrinepre-clinicalreceptorscreeningtherapeutic targettranscription factortumortumor DNAtumor growth
项目摘要
Abstract/Summary:
Various types of endocrine therapy have been used for postmenopausal women with early stage breast
cancer. These therapies are safe and effective, but initially responsive breast tumors often develop resistance
and eventually recur. Since a communication between tumor and tumor circumstance plays an important role to
grow tumor and spread tumor to secondary organs, we examined the communication of endocrine resistant
breast cancer with stroma which is the part of a tissue or organ that has a connective and structural role in
cancer. We established four different endocrine resistant breast cancer cell lines and examined the
communication of these cells with four stromal cells. We found that CCL5 and endoglin might play an important
role in endocrine resistant breast cancer. Thus, we will 1) Investigate the role of CCL5 and endoglin in the
crosstalk between ERBC cells and stromal cells, 2) Unveil the mechanism of the upregulated CCL5 and endoglin
in crosstalk between ERBC and stroma, and 3) Develop therapeutic strategies to block the paracrine interaction
between the stromal cell and ERBC cell.
We will investigate which secreted factors could serve as a key regulator in the transition of breast cancer
cells to endocrine resistance and gaining of an aggressive phenotype. Further, secreted factors from the
communication between endocrine resistant breast cancer and stroma might prove to be an attractive target for
breast cancer drugs. Most of the cancer drugs in use currently have been developed to directly impact tumor
cells. These drugs do not do much to block signals coming from tumor circumstance. Our proposed investigation
will give us a small list of the most potent of these signals. Drugs, some of which we will identify here, and others
that will have to be developed, that block these signals could limit the ability of the tumors to spread to secondary
organs, which should result in overall survival gains for patients.
摘要/总结:
项目成果
期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Crosstalk between triple negative breast cancer and microenvironment.
- DOI:10.18632/oncotarget.28397
- 发表时间:2023-03-31
- 期刊:
- 影响因子:0
- 作者:Smrekar, Karly;Belyakov, Artem;Jin, Kideok
- 通讯作者:Jin, Kideok
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Kideok Jin其他文献
Kideok Jin的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Delays in Acquisition of Oral Antineoplastic Agents
口服抗肿瘤药物的获取延迟
- 批准号:
9975367 - 财政年份:2020
- 资助金额:
$ 48万 - 项目类别:
Eliminate the difficulty of venous puncture in patients receiving antineoplastic agents - Development of a new strategy for the prevention of induration-
消除接受抗肿瘤药物的患者静脉穿刺的困难 - 制定预防硬结的新策略 -
- 批准号:
16K11932 - 财政年份:2016
- 资助金额:
$ 48万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Molecular mechanisms of the antineoplastic agents inhibiting DNA replication and their applications to cancer patient treatmen
抗肿瘤药物抑制DNA复制的分子机制及其在癌症患者治疗中的应用
- 批准号:
19591274 - 财政年份:2007
- 资助金额:
$ 48万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
PNET EXPERIMENTAL THERAPEUTICS--ANTINEOPLASTIC AGENTS AND TREATMENT DELIVERY
PNET 实验治疗——抗肿瘤药物和治疗实施
- 批准号:
6346309 - 财政年份:2000
- 资助金额:
$ 48万 - 项目类别:
TYROSINE KINASE INHIBITORS AS ANTINEOPLASTIC AGENTS
酪氨酸激酶抑制剂作为抗肿瘤剂
- 批准号:
2885074 - 财政年份:1999
- 资助金额:
$ 48万 - 项目类别:
TYROSINE KINASE INHIBITORS AS ANTINEOPLASTIC AGENTS
酪氨酸激酶抑制剂作为抗肿瘤剂
- 批准号:
6174221 - 财政年份:1999
- 资助金额:
$ 48万 - 项目类别: